Shanghai Henlius Biotech, Inc.
HKSE: 2696.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jun Zhu
- Employees
- 3,515
- Headquarters
- Shanghai, China
- IPO year
- 2019
- Market cap
- HK$40.0B
- Website
- https://www.henlius.com
Loading 2696…
Loading profile data…Frequently asked questions about 2696
What does Shanghai Henlius Biotech, Inc. (2696.HK) do?
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastu...
Where does 2696.HK trade?
Shanghai Henlius Biotech, Inc. (2696.HK) trades on the Hong Kong Stock Exchange.
What sector is 2696.HK in?
Shanghai Henlius Biotech, Inc. (2696.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Shanghai Henlius Biotech, Inc.?
Jun Zhu is the chief executive officer of Shanghai Henlius Biotech, Inc. (2696.HK).
Where is Shanghai Henlius Biotech, Inc. headquartered?
Shanghai Henlius Biotech, Inc. is headquartered in China.
Does 2696.HK pay a dividend?
Shanghai Henlius Biotech, Inc. (2696.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2696.HK go public?
Shanghai Henlius Biotech, Inc. (2696.HK) completed its initial public offering in 2019.